Bayer

Bayer’s asundexian demonstrated a substantial, 26 percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo

06 Feb 2026

Nubeqa™ (darolutamide) receives third approval in China for men with advanced prostate cancer

03 Feb 2026

Finerenone recommended for the treatment of patients with heart failure with LVEF ≥40% in the EU

30 Jan 2026

Bayer to Present New Phase III Data and Advancements of Radiology Portfolio at ECR 2026

26 Jan 2026

FDA grants Orphan Drug Designation to BlueRock Therapeutics’ investigational cell therapy OpCT-001

22 Jan 2026

Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

20 Jan 2026

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

20 Jan 2026

Eylea™ 8 mg approved in the EU for third retinal indication

20 Jan 2026

Bayer Accelerates Pharma Growth on High-Value Portfolio

20 Jan 2026

Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus

13 Jan 2026

View details about the software product Informachine News Trackers